The concept behind the Pharmaceutical Development Digest (PDD) was is to create a tool that evaluates, synthesizes, and repackages pharmaceutical and medical device industry intelligence – distilling vast amounts of information and transforming it into concise, usable knowledge.
The road from discovery to market in the pharmaceutical and medical device industry is a long and complicated one. The clinical trial process is the crux of the success or failure of a product. Clinical research and regulatory events are the critical elements that determine where, when, and how companies allocate their marketing spend. Understanding the complex science that drives the approval process is crucial to comprehending the needs of your clients, but the language of science can be difficult to understand. PDD provides easy to understand explanations of a product’s mechanism of action and brief consistently formatted descriptions of the clinical trials that are the basis of the regulatory approval process. PDD delivers a thorough, but concise rolling 3-year historical review of the development the industry has deemed most important, ensuring that sales staff are knowledgeable about the issues and events that are most important to their client.
The PDD is a monthly surveillance service designed to help those who sell products or services to the pharmaceutical and medical device industries stay apprised of the latest industry developments; the events that are most important to their customers. Unlike a searchable database where it’s necessary to know what you’re looking for in order to get reliable results and useful information, the PDD filters out the irrelevant and extraneous information to deliver only the most important, recent, and germane pharmaceutical and medical device industry updates (clinical trial and regulatory developments) in an easy to use format.
Decades of experience in medical publishing and selling to the pharmaceutical and medical device industries globally provide the Publishers of Greylock Press with both an intimate understanding of how frustrating and time consuming it can be to stay abreast of new developments and the experience to sift through volumes of information and extract the most important and relevant nuggets that are vital to your company’s success. This is the tool we would have loved to have had when we were selling to the industry.
The information provided in the PDD is difficult, time consuming, and costly to find, but essential for sales in this field. PDD delivers your business strategy, sales, and marketing departments the information they need to focus their efforts on the industry segments and products that are most important to their clients.
The Topline Summary Section provides the reader with a visual snapshot of the current regulatory status for all of the products tracked in PDD.
The reader is able to quickly determine:
- currently approved products
- products that are likely be approved within the coming year
- products that will be approved next year
- products that are at least several years from approval
The Topline Data section of the Pharma Development Digest (PDD) provides a concise snapshot of industry activity organized alphabetically by company (and by generic name within a company) – allowing for a quick assessment of which products are most important and most active. This section also provides the reader with a quick overview of activity (and the nature of that activity) associated with a particular product. Color-coding is the key to what is important now and over the next 12-24 months allowing for strategically focused efforts:
- Entries in dark green indicate an approved product with a large revenue potential
- Light green entries are for approved products with a lower revenue potential due to a small patient population or a restrictive approved indication
- All product entries are yellow until they are approved either in the EU or in the US
- The palest yellow indicates that there is only clinical trial activity associated with a product
- Once there is regulatory activity associated with a product the entry is a darker yellow
- The darkest shade of yellow indicates a positive CHMP or FDA advisory committee positive opinion indicating approval is imminent
- A negative clinical trial or regulatory event is shaded red allowing the reader to quickly ascertain events that could negatively impact revenues
The Product Detail section of the PDD provides an easy to understand description of the product and it’s mechanism of action, as well as the product’s drug class and which indications have been approved or are being investigated in clinical trials. This section presents a rolling 3-year product history with detailed descriptions of the nature of activity associated with each product, highlighting the science that is the basis for regulatory activity, and providing timely information that is most likely to impact a company’s marketing spend.
Products by Indication
The Products by Indication section of the PDD puts all of the information contained in the report into perspective, providing the reader a quick summary of competing products, their product class, and their regulatory status in the EU and US.
Global Sales by Product:
This section provides a snapshot of the sales history for approved products over the past three years and the most recent four quarters. All sales figures are reported in US$.
Notes: 1) All revenues are recorded in US Dollars, some companies report their revenues in currencies other than US Dollars, in the event that a company reports in a currency other than dollars, the reported figures are converted to USD as at the exchange rate on the last day of the reporting period. 2) All figures come from unaudited quarterly reports filed to stockholders. Therefore, the quarterly totals may not equal the annual total. 3) Green indicates growth (in US Dollars) red indicates contracting sales. 4) If data is not available, it is indicated by n/a. “0” indicates no sales for the period. 5) Top number represents global sales, numbers in parenthesis “(US66)” represent sales within the United States. If there are no numbers in parenthesis, than only global data is provided.